X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1311) 1311
Publication (112) 112
Book Review (23) 23
Book Chapter (7) 7
Conference Proceeding (2) 2
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1196) 1196
male (1005) 1005
prostate cancer (652) 652
index medicus (645) 645
prostatic neoplasms - drug therapy (567) 567
oncology (554) 554
combined modality therapy (495) 495
aged (466) 466
antineoplastic combined chemotherapy protocols - therapeutic use (450) 450
middle aged (412) 412
cancer (397) 397
androgen antagonists - therapeutic use (379) 379
prostatic neoplasms - pathology (355) 355
urology & nephrology (334) 334
treatment outcome (311) 311
care and treatment (280) 280
prostatic neoplasms - therapy (276) 276
chemotherapy (259) 259
antineoplastic agents, hormonal - therapeutic use (225) 225
aged, 80 and over (212) 212
orchiectomy (193) 193
prostate-specific antigen - blood (192) 192
radiotherapy (190) 190
carcinoma (186) 186
prostatic neoplasms - mortality (182) 182
animals (180) 180
combined androgen blockade (180) 180
prostatic neoplasms - surgery (174) 174
metastasis (168) 168
female (167) 167
therapy (160) 160
radical prostatectomy (159) 159
research (154) 154
docetaxel (153) 153
health aspects (152) 152
neoplasm staging (149) 149
prostatic neoplasms - radiotherapy (138) 138
survival (137) 137
prognosis (135) 135
androgen antagonists - administration & dosage (132) 132
flutamide (131) 131
medicine & public health (131) 131
antineoplastic agents - therapeutic use (126) 126
survival rate (126) 126
prostatic neoplasms - blood (117) 117
antineoplastic combined chemotherapy protocols - adverse effects (112) 112
adult (110) 110
disease-free survival (110) 110
neoplasm metastasis (110) 110
prostate (110) 110
adenocarcinoma - drug therapy (109) 109
disease progression (108) 108
castration (107) 107
men (107) 107
follow-up studies (106) 106
prostatectomy (106) 106
tumors (106) 106
androgens (102) 102
double-blind (101) 101
immunotherapy (100) 100
clinical trials (99) 99
survival analysis (97) 97
analysis (95) 95
antineoplastic agents, hormonal - administration & dosage (94) 94
cell line, tumor (94) 94
drug therapy (92) 92
risk factors (91) 91
taxoids - administration & dosage (91) 91
quality of life (90) 90
time factors (89) 89
clinical trials as topic (88) 88
radiation-therapy (88) 88
retrospective studies (88) 88
antineoplastic combined chemotherapy protocols - pharmacology (87) 87
mice (87) 87
urology (87) 87
randomized controlled trials as topic (84) 84
cancer therapies (83) 83
flutamide - administration & dosage (83) 83
hematology, oncology and palliative medicine (83) 83
phase-iii trial (82) 82
apoptosis (81) 81
trial (81) 81
endocrinology & metabolism (80) 80
prostatic neoplasms, castration-resistant - drug therapy (80) 80
bone neoplasms - secondary (77) 77
chemotherapy, adjuvant (77) 77
pharmacology & pharmacy (77) 77
expression (75) 75
metastases (75) 75
flutamide - therapeutic use (74) 74
androgen antagonists - adverse effects (72) 72
patient outcomes (71) 71
prostatic neoplasms - metabolism (71) 71
article (70) 70
bicalutamide (70) 70
antineoplastic combined chemotherapy protocols - administration & dosage (69) 69
development and progression (69) 69
hormonal-therapy (68) 68
neoadjuvant therapy (68) 68
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1272) 1272
Japanese (20) 20
German (14) 14
French (6) 6
Spanish (6) 6
Chinese (5) 5
Russian (2) 2
Serbian (2) 2
Italian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 08/2009, Volume 115, Issue 15, pp. 3437 - 3445
Journal Article
Journal Article
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2008, Volume 22, Issue 2, pp. 331 - 340
Maximal androgen blockade (MAB) refers to the combination of medical (gonadotrophin-releasing hormone agonist) or surgical castration with an anti-androgen for... 
Endocrinology & Metabolism | prostate cancer | anti-androgens | androgen receptor | maximal androgen blockade | TRIALS | METAANALYSIS | MONOTHERAPY | FLUTAMIDE | WITHDRAWAL SYNDROME | BICALUTAMIDE | NONSTEROIDAL ANTIANDROGENS | THERAPY | ENDOCRINOLOGY & METABOLISM | CARCINOMA | AGONIST | Meta-Analysis as Topic | Anilides - adverse effects | Humans | Androgen Antagonists - economics | Male | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Orchiectomy - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - economics | Antineoplastic Agents, Hormonal - economics | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Antineoplastic Agents, Hormonal - administration & dosage | Combined Modality Therapy - adverse effects | Withholding Treatment | Disease Progression | Prostatic Neoplasms - mortality | Randomized Controlled Trials as Topic | Tosyl Compounds - adverse effects | Anilides - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Androgen Antagonists - administration & dosage | Neoplasms, Hormone-Dependent - drug therapy | Androgen Antagonists - adverse effects | Neoplasm Staging | Nitriles - adverse effects | Orchiectomy - methods | Prostate cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 62, pp. 105458 - 105462
This study analyzed 99Tcm-MDP bone scans and investigated factors influencing early-stage castration resistance in prostate cancer (CRPC) patients with bone... 
Castration resistance | Combined androgen blockade | Bone metastasis | Prostate cancer | Bone scan | SURVIVAL | DEPRIVATION THERAPY | prostate cancer | bone metastasis | castration resistance | UPDATE | bone scan | combined androgen blockade | ANTIGEN | CELL BIOLOGY
Journal Article
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 12/2018, Volume 9, Issue 97, pp. 36966 - 36974
The aim of our retrospective study was to determine the time to progression to castration-resistant prostate cancer (CRPC) in prostate cancer patients who... 
Castration-resistant prostate cancer | Progression | Combined androgen blockade | Survival | Hormone-sensitive prostate cancer
Journal Article